Avandia remains on the market in the US despite serious health issues that include more than a 50% increase in heart attacks and mortality. All three "glitazones" have safety issues. Rezulin was taken off the market more than a decade ago because of severe liver disease. The third drug, Actos, remains suspicious but up to this point seems to be somewhat safer than Avandia. Unfortunately, economics trump service in the pharmaceutical industry. It has been estimated that more than 50,000 deaths have occurred from Avandia.
